Premium
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Cortex Pharmaceuticals, Inc. (NYSE Amex: COR) announced that it has received notification from the NYSE Amex LLC indicating that, due to the Company’s non-compliance with...
Cortex Pharmaceuticals, Inc. (NYSE Amex (COR)) reported a net loss applicable to common stock of $3,243,000, or $0.06 per share for the quarter ended September 30, 2009 compared...
Cortex Pharmaceuticals, Inc. (NYSE Amex: COR) President and CEO, Mark A. Varney, Ph.D., will present at Rodman & Renshaw’s Eleventh Annual Healthcare Conference taking place...
Cortex Pharmaceuticals, Inc. (NYSE Amex (COR)) reported that it has received a delisting notification from the NYSE Amex LLC indicating that it has not accepted the Company’s...
Cortex Pharmaceuticals, Inc. (NYSE Amex: COR) reported a net loss applicable to common stock of $2,778,000, or $0.06 per share for the quarter ended June 30, 2009 compared with...
Cortex Pharmaceuticals, Inc. (NYSE Amex: COR) reported that it has entered into a definitive agreement with a single institutional investor related to a private placement of its...
Cortex Pharmaceuticals, Inc. (NYSE Amex: COR), a neuroscience company focused on developing novel AMPAKINE? drug therapies for neurological and psychiatric disorders, will web...
Cortex Pharmaceuticals, Inc. (NYSE Amex: COR) reported that it has received notice from the NYSE Amex LLC indicating that the company is not in compliance with certain of the...
Cortex Pharmaceuticals, Inc. (NYSE Amex: COR) reported a net loss of $3,168,000, or $0.07 per share for the quarter ended March 31, 2009 compared with a net loss of $4,371,000...
Cortex Pharmaceuticals, Inc. (NYSE Amex:COR) announced that it has completed the previously announced sale of shares of a newly-designated series of convertible preferred stock...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
